...
首页> 外文期刊>Cancer Medicine >Incidence of cardiovascular disease up to 13?year after cancer diagnosis: A matched cohort study among 32?757 cancer survivors
【24h】

Incidence of cardiovascular disease up to 13?year after cancer diagnosis: A matched cohort study among 32?757 cancer survivors

机译:癌症诊断后长达13年的心血管疾病发生率:一项针对32 757名癌症幸存者的队列研究

获取原文
           

摘要

We examined the incidence of cardiovascular disease (CVD) among 32?757 cancer survivors and age‐, gender‐, and geographically matched cancer‐free controls during a follow‐up period of 1‐13?years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1‐year cancer survivors without a history ofCVD diagnosed with breast (n?=?6762), prostate (n?=?4504), non‐Hodgkin (n?=?1553), Hodgkin (n?=?173), lung and trachea (n?=?2661), basal cell carcinoma (BCC; n?=?12?476), and colorectal (n?=?4628) cancer during 1999‐2011 were selected from the Netherlands Cancer Registry and matched to cancer‐free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95%CI: 1.01‐1.35) and lung and trachea (HR: 1.48; 95%CI: 1.10‐1.97) cancer survivors had an increased risk for developingCVD compared to cancer‐free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95%CI: 1.06‐1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non‐Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer‐free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age‐, gender‐ and geographically matched cancer‐free controls. Studies including longer follow‐up periods are warranted to examine whether cancer survivors are at increased risk of long‐term incidentCVD.
机译:我们在1-13年的随访期内检查了32?757名癌症幸存者以及年龄,性别和地理匹配的无癌对照组中心血管疾病(CVD)的发生率,并探讨了CVD发生率是否因接受治疗而有所不同癌症治疗,传统的心血管危险因素,年龄或性别。没有CVD史的成年1年癌症幸存者被诊断为乳房(n?=?6762),前列腺(n?=?4504),非霍奇金(n?=?1553),霍奇金(n?=?173),从荷兰癌症登记处选择了1999-2011年间的肺癌和气管癌(n?=?2661),基底细胞癌(BCC; n?=?12?476)和结直肠癌(n?=?4628)并与没有CVD史的无癌对照。来自PHARMO数据库网络的药物分发和住院治疗被用作CVD的代理。使用Cox回归分析对数据进行分析。前列腺癌(HR:1.17; 95%CI:1.01-1.35)和肺气管(HR:1.48; 95%CI:1.10-1.97)与无癌对照组相比,癌症幸存者发生CVD的风险增加。在包括传统的心血管危险因素和癌症治疗信息之后,肺癌和气管癌幸存者中这种增加的风险仍然具有统计学意义(HR:1.41; 95%CI:1.06-1.89)。在前列腺癌幸存者中,发生CVD的风险增加仅限于那些接受激素的人和没有传统心血管危险因素的人。与无癌对照相比,乳腺癌,非霍奇金,BCC和结直肠癌幸存者未显示CVD风险增加。与年龄,性别和地理匹配的无癌对照相比,前列腺癌,肺癌和气管癌幸存者中发生CVD的风险增加。有必要进行包括更长随访时间在内的研究,以检查癌症幸存者是否长期发生CVD的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号